Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Robert R. Bies
Author Correction: Pharmacological markers of HIV prevention for oral pre-exposure prophylaxis in men who have sex with men
Correction to: Nature Communications https://doi.org/10.1038/s41467-026-72907-6, published online 10 May 2026 In the version of this article initially published, there was a typographical error in the Fig. 4b x-axis label, where in the text now reading “Δt = time of exposure – time of first dose (hours),” “hours” appeared originally as “days.” The figure is now updated in the HTML and PDF versions of the article.
Pharmacological markers of HIV prevention for oral pre-exposure prophylaxis in men who have sex with men
|
Abstract The human immunodeficiency virus (HIV) infected approximately 1.1 million individuals in 2024. There is no effective vaccine or cure, and funding cuts in resource-limited settings threaten treatment access. Cost-effective and widely available prevention strategies, such as oral emtricitabine/tenofovir disoproxil fumarate pre-exposure prophylaxis (FTC/TDF-PrEP), are therefore essential.
By Sara Iannuzzi, Malin Müller, Yifan Yu Verified, Lanxin Zhang, Craig Hendrix, Robert R. Bies, Max von Kleist
|
Nature
Verified
Simulating realistic patient profiles from pharmacokinetic models by a machine learning postprocessing correction of residual variability
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC? The problem of adequate characterization of residual variability (RUV) in population pharmacokinetics has been the subject of many proposals, which mostly address heteroscedasticity while one of the main contributors of RUV is also model misspecification. WHAT QUESTION DID THIS STUDY ADDRESS?
Model‐Based Prediction of Irinotecan‐Induced Grade 4 Neutropenia in Cancer Patients: Influence of Incorporating Germline Genetic Factors in the Model
CONFLICT OF INTEREST R.R.B. has received funding from the US Department of Defense, NICHD, NIDA, NIAID, and USAID. He has also received funding as an expert consultant for Janssen through Belmore Neidrauer LLP, St. Gobain LLC, and serves on the DSMB for KeifeRX. He is a consultant for Advanced Biosciences Laboratories. F.I. is an AbbVie employee and receives stocks from AbbVie. S.K. is an employee of and owns stock in Pfizer. None of this work was done in conjunction with Pfizer.
Modelling the progression of illicit substance use patterns from real‐world evidence
CONFLICT OF INTEREST STATEMENT Hari Prabhath Tummala has no conflicts. Dr. Bies receives grant funding from NIDA, NIAID, NICHD, USAID, and the Bill and Melinda Gates Foundation and serves as a consultant for Advanced Biosciences Laboratories (NIAID). In the past he has served as a consultant for Lumos Biopharma through NGT Biopharma Consultants.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Robert R.
Contact Robert R., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack